# A Study of Genolair in Two Dosage Forms (Solution and Lyophilisate) and Xolair® in Healthy Volunteers

> **NCT06494345** · PHASE1 · COMPLETED · sponsor: **AO GENERIUM** · enrollment: 180 (actual)

## Conditions studied

- Allergic Asthma

## Interventions

- **BIOLOGICAL:** Genolair, solution for subcutaneous administration, 150 mg
- **BIOLOGICAL:** Genolair, lyophilisate for the preparation of solution for subcutaneous administration
- **BIOLOGICAL:** Xolair®, solution for subcutaneous administration, 150 mg

## Key facts

- **NCT ID:** NCT06494345
- **Lead sponsor:** AO GENERIUM
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-15
- **Primary completion:** 2024-06-09
- **Final completion:** 2024-06-09
- **Target enrollment:** 180 (ACTUAL)
- **Last updated:** 2024-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06494345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06494345, "A Study of Genolair in Two Dosage Forms (Solution and Lyophilisate) and Xolair® in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06494345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*